Axsome Therapeutics Inc’s recent filing unveils that its General Counsel Murdock Hunter R. unloaded Company’s shares for reported $0.77 million on Jun 20 ’25. In the deal valued at $102.47 per share,7,500 shares were sold. As a result of this transaction, Murdock Hunter R. now holds 0 shares worth roughly $0.0.
Then, Murdock Hunter R. sold 6,014 shares, generating $602,122 in total proceeds. Upon selling the shares at $100.12, the General Counsel now owns 0 shares.
Before that, Murdock Hunter R. bought 6,014 shares. Axsome Therapeutics Inc shares valued at $602,101 were divested by the Officer at a price of $100.12 per share.
Oppenheimer initiated its Axsome Therapeutics Inc [AXSM] rating to an Outperform in a research note published on June 03, 2025; the price target was $185. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in early April with a ‘”a Buy”‘ rating. Deutsche Bank began covering AXSM with “Buy” recommendation on February 11, 2025. Mizuho maintained its rating on December 31, 2024. It rated AXSM as “an Outperform”.
Price Performance Review of AXSM
On Tuesday, Axsome Therapeutics Inc [NASDAQ:AXSM] saw its stock jump 2.57% to $104.26. Over the last five days, the stock has gained 2.53%. Axsome Therapeutics Inc shares have risen nearly 38.68% since the year began. Nevertheless, the stocks have risen 23.22% over the past one year. While a 52-week high of $139.13 was reached on 02/21/25, a 52-week low of $72.21 was recorded on 01/10/25.
Levels Of Support And Resistance For AXSM Stock
The 24-hour chart illustrates a support level at 101.47, which if violated will result in even more drops to 98.68. On the upside, there is a resistance level at 106.04. A further resistance level may holdings at 107.81.
How much short interest is there in Axsome Therapeutics Inc?
A steep rise in short interest was recorded in Axsome Therapeutics Inc stocks on 2025-05-30, dropping by -0.31 million shares to a total of 3.88 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 4.2 million shares. There was a decline of -8.01%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 03, 2024 when Wells Fargo began covering the stock and recommended ‘”an Overweight”‘ rating along with a $140 price target.
